1. Anaplastic lymphoma kinase tyrosine kinase inhibitors associated gastrointestinal obstruction, perforation, and ulceration: an analysis of the FDA adverse event reporting system database (FAERS)
   Jing Huang et al, 2022, International Journal of Clinical Pharmacy CrossRef
2. In vitro investigation of the binding characteristics of dacomitinib to human α 1-acid glycoprotein: Multispectral and computational modeling
   Zhe-Ying Hu et al, 2024, Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy CrossRef
3. Progression patterns, resistant mechanisms and subsequent therapy for ALK-positive NSCLC in the era of second-generation ALK-TKIs
   Lige Wu et al, 2024, Journal of Translational Medicine CrossRef
4. Interstitial lung disease risk of anaplastic lymphoma kinase tyrosine kinase inhibitor treatment of non-small cell lung cancer: a real-world pharmacovigilance study
   Min Zhao et al, 2023, Expert Opinion on Drug Safety CrossRef
5. Safety of Surgery after Neoadjuvant Targeted Therapies in Non-Small Cell Lung Cancer: A Narrative Review
   Tomasz Marjanski et al, 2021, International Journal of Molecular Sciences CrossRef
6. Targeting Wnt/Beta-Catenin Signaling in HPV-Positive Head and Neck Squamous Cell Carcinoma
   Faris F. Brkic et al, 2022, Pharmaceuticals CrossRef
7. Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Associated Cardiotoxicity: A Recent Five-Year Pharmacovigilance Study
   Yihan Liu et al, 2022, Frontiers in Pharmacology CrossRef
8. Real-World Treatment and Outcomes of ALK-Positive Metastatic Non–Small Cell Lung Cancer in a Southeast Asian Country
   Mau Ern Poh et al, 2023, Cancer Management and Research CrossRef
9. Active and machine learning-enhanced discovery of new FGFR3 inhibitor, Rhapontin, through virtual screening of receptor structures and anti-cancer activity assessment
   Qingxin Zeng et al, 2024, Frontiers in Molecular Biosciences CrossRef
10. Cardiac arrhythmias associated with anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS)
    Feifei Wang et al, 2023, Expert Opinion on Drug Safety CrossRef